Cargando…

Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How

The natural history of follicular lymphoma is usually characterized by an indolent course with a high response rate to the first line therapy followed by recurrent relapses, with a time to next treatment becoming shorter after each subsequent treatment line. More than 80% of patients have advanced s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pavanello, Francesca, Steffanoni, Sara, Ghielmini, Michele, Zucca, Emanuele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111519/ https://www.ncbi.nlm.nih.gov/pubmed/27872742 http://dx.doi.org/10.4084/MJHID.2016.062

Ejemplares similares

Controversies in the Treatment of Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2020)

Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
por: Chau, I, et al.
Publicado: (2003)

Freeze-all, for whom, when, and how
por: Celada, Paula, et al.
Publicado: (2020)

Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?
por: Jourde-Chiche, Noémie, et al.
Publicado: (2023)

In search of the optimal proteosome inhibitor. How, when and for whom?
por: Engelhardt, Monika, et al.
Publicado: (2021)

Radiotherapy in Pancreatic Cancer: To Whom, When, and How?
por: Falco, Michał, et al.
Publicado: (2023)

Electroconvulsive therapy following incident bipolar disorder: When, how, and for whom?
por: Salagre, Estela, et al.
Publicado: (2022)

Non-invasive ventilation in the ED: Whom, When, How?
por: Göksu, Erkan, et al.
Publicado: (2018)

To immunosuppress: whom, when and how? That is the question with COVID-19
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom?
por: Orvieto, Raoul
Publicado: (2015)

Defibrillation Testing of the Implantable Cardioverter Defibrillator: When, How, and by Whom?
por: Pires, Luis A
Publicado: (2007)

Prone position in ARDS patients: why, when, how and for whom
por: Guérin, Claude, et al.
Publicado: (2020)

Pediatric Percutaneous Endoscopic Gastrostomy in Korea - When? By Whom? How?
por: Lee, Yoon
Publicado: (2022)

Editorial: Personalized nutrition with polyphenols—which, for whom, when and how?
por: Weseler, Antje R., et al.
Publicado: (2023)

Intradialytic parenteral nutrition for patients on hemodialysis: when, how and to whom?
por: Carrero, Juan J, et al.
Publicado: (2022)

Risk factors for renal toxicity after inpatient cisplatin administration
por: Galfetti, Elena, et al.
Publicado: (2020)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Salvage radiotherapy with or without hormone therapy: for whom and when?
por: Carrie, Christian
Publicado: (2017)

Severe Asthma and Biological Therapy: When, Which, and for Whom
por: Rogliani, Paola, et al.
Publicado: (2019)

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
por: Wang, Yucai, et al.
Publicado: (2022)

Noninvasive respiratory support for COVID-19 patients: when, for whom, and how?
por: Sullivan, Zachary P., et al.
Publicado: (2022)

How we treat primary central nervous system lymphoma
por: Calimeri, T., et al.
Publicado: (2021)

Checkpoint and PARP inhibitors, for whom and when
por: Lee, Jung-Min, et al.
Publicado: (2017)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
por: Karaiskos, Ilias, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
por: Wu, Jia-Feng
Publicado: (2022)

Oncoplastic Breast Surgery: What, When and for Whom?
por: Macmillan, R. Douglas, et al.
Publicado: (2016)

COVID-19 patients: when and whom to ventilate?
por: Lal, Tusharindra, et al.
Publicado: (2020)

Midwifery continuity of care: A scoping review of where, how, by whom and for whom?
por: Bradford, Billie F., et al.
Publicado: (2022)

Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas
por: Sorigue, Marc, et al.
Publicado: (2022)

Prospects in the management of patients with follicular lymphoma beyond first-line therapy
por: Qualls, David, et al.
Publicado: (2022)

Implant retention after acute and hematogenous periprosthetic hip and knee infections: Whom, when and how?
por: Triantafyllopoulos, Georgios K, et al.
Publicado: (2016)

Emergency airway management – by whom and how?
por: Sollid, S. J. M., et al.
Publicado: (2016)

Laparoscopy in Blunt Abdominal Trauma: for Whom? When?and Why?
por: Justin, Viktor, et al.
Publicado: (2017)

Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?
por: Na, Soo-Young, et al.
Publicado: (2021)

Genetic testing in focal segmental glomerulosclerosis: in whom and when?
por: Tato, Ana María, et al.
Publicado: (2023)

Follicular lymphoma and marginal zone lymphoma: how many diseases?
por: Laurent, Camille, et al.
Publicado: (2022)

How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity
por: Grass, G. Daniel, et al.
Publicado: (2016)

How, when, and for whom: decisions regarding remote neuropsychological assessment during the 2020 COVID-19 pandemic
por: Bloch, Ayala, et al.
Publicado: (2021)

Cardiomyopathy Induced by Artificial Cardiac Pacing: To Whom, When, Why, and How? Insights on Heart Failure Development
por: Ferrari, Andres Di Leoni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aaf79evbs4lbslfe0aas28qgi2